Cooperative Interaction Between Mutant P53 and Des(1-3)IGF-I Accelerates Mammary Tumorigenesis
Overview
Affiliations
Mammary tumorigenesis was analysed in transgenic mice which overexpress des(1-3)hIGF-I (WAP-DES) and/or a mutant form of p53 (p53172R-H). Nonlactating, multiparous WAP-DES mice exhibited hyperplastic lesions termed mammary interepithelial neoplasia (MIN) which constitutively expressed WAP-DES. By 23 months of age, 53% of the WAP-DES mice developed mammary adenocarcinomas. A 75% reduction in both apoptosis and proliferation was observed in the normal mammary glands of WAP-DES mice. Mammary tumor incidence in WAP-DES/p53 bitransgenic mice was similar to that of WAP-DES and 2 - 3-fold greater than that of nontransgenic and p53172R-H females. Tumor latency, however, was reduced by 8 months in bitransgenic mice as compared to mice of the other three genotypes. Aneuploidy was frequently observed in tumors from bitransgenic and p53172R-H mice, but not from mice expressing only the WAP-DES transgene. Expression of IGFBP3 was elevated in tumors from WAP-DES, but not bitransgenic mice, indicating an alteration in the p53/IGF-I axis. These studies indicate that overexpression of des(1-3)hIGF-I increases the frequency of MIN and stochastic mammary tumors and that the appearance of tumors displaying genomic instability is accelerated by mutant p53172R-H. Oncogene (2000) 19, 889 - 898.
Umehara H, Maekawa Y, Koizumi F, Shimizu M, Ota T, Fouad T Ther Adv Med Oncol. 2018; 10:1758835918786858.
PMID: 30083253 PMC: 6066809. DOI: 10.1177/1758835918786858.
Insulin resistance and hepatocarcinogenesis.
Sasaki Y Clin J Gastroenterol. 2015; 3(6):271-8.
PMID: 26190483 DOI: 10.1007/s12328-010-0177-6.
Trp53 regulates Notch 4 signaling through Mdm2.
Sun Y, Klauzinska M, Lake R, Lee J, Santopietro S, Raafat A J Cell Sci. 2011; 124(Pt 7):1067-76.
PMID: 21402876 PMC: 3056605. DOI: 10.1242/jcs.068965.
Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer.
Tamimi R, Colditz G, Wang Y, Collins L, Hu R, Rosner B Breast Cancer Res Treat. 2011; 128(1):243-50.
PMID: 21197570 PMC: 3116083. DOI: 10.1007/s10549-010-1313-1.
The insulin-like growth factor pathway as a target for cancer therapy.
Lopez-Calderero I, Sanchez Chavez E, Garcia-Carbonero R Clin Transl Oncol. 2010; 12(5):326-38.
PMID: 20466617 DOI: 10.1007/s12094-010-0514-8.